SIRPA and neoplasm: (3) ALX148 (Evorpacept), an engineered fusion protein comprising a modified SIRPαD1 domain and inactive human IgG1 Fc, binds CD47 with high affinity to block interactions with native SIRPα. ALX148 promotes innate anti-tumor immunity by increasing macrophage phagocytosis, DC activation, and inflammatory TAM polarization.